School of Stomatology, Fujian Medical University, Fuzhou, Fujian 350000, China.
Fujian Biological Materials Engineering and Technology Center of Stomatology, Fuzhou, Fujian 350000, China.
Biomed Res Int. 2019 Mar 17;2019:7267062. doi: 10.1155/2019/7267062. eCollection 2019.
To date, it remains unknown whether the addition of platelet-rich fibrin (PRF) to bone grafts actually improves the effectiveness of maxillary sinus augmentation. This study aimed to perform a meta-analysis to evaluate the efficacy of PRF in sinus lift.
PubMed, Embase, and the Cochrane Library were searched. Randomized controlled studies were identified. The risk of bias was evaluated using the Cochrane Collaboration tool.
Five RCTs were included in our meta-analysis. Clinical, radiographic, and histomorphometric outcomes were considered. No implant failure or graft failure was detected in all included studies within the follow-up period. The percentage of contact length between newly formed bone substitute and bone in the PRF group was lower but lacked statistical significance (3.90%, 95% CI, -2.91% to 10.71%). The percentages of new bone formation (-1.59%, 95% CI, -5.36% to 2.18%) and soft-tissue area (-3.73%, 95% CI, -10.11% to 2.66%) were higher in the PRF group but were not significantly different. The percentage of residual bone graft was not significant in either group (4.57%, 95% CI, 0% to 9.14%).
Within the limitations of this review, it was concluded that there were no statistical differences in survival rate, new bone formation, contact between newly formed bone and bone substitute, percentage of residual bone graft (BSV/TV), and soft-tissue area between the non-PRF and PRF groups. Current evidence supporting the necessity of adding PRF to bone graft in sinus augmentation is limited.
迄今为止,添加富血小板纤维蛋白(PRF)是否能提高上颌窦提升中骨移植的效果仍不清楚。本研究旨在进行荟萃分析以评估 PRF 在窦提升中的疗效。
检索了 PubMed、Embase 和 Cochrane 图书馆。确定了随机对照研究。使用 Cochrane 协作工具评估偏倚风险。
我们的荟萃分析纳入了 5 项 RCT。考虑了临床、影像学和组织形态计量学结果。在所有纳入研究的随访期内,均未发现种植体失败或移植物失败。PRF 组新形成的骨替代物与骨之间的接触长度百分比较低,但无统计学意义(3.90%,95%CI,-2.91%至 10.71%)。PRF 组新骨形成的百分比(-1.59%,95%CI,-5.36%至 2.18%)和软组织面积的百分比(-3.73%,95%CI,-10.11%至 2.66%)较高,但无统计学差异。两组的剩余骨移植物百分比均不显著(4.57%,95%CI,0%至 9.14%)。
在本综述的限制范围内得出结论,在存活率、新骨形成、新形成的骨与骨替代物之间的接触、剩余骨移植物百分比(BSV/TV)和软组织面积方面,非 PRF 组与 PRF 组之间无统计学差异。目前支持在窦提升中添加 PRF 必要性的证据有限。